Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;19(4):284-9.
doi: 10.5114/wo.2015.54387. Epub 2015 Sep 28.

Overall survival and disease-free survival in breast cancer patients treated at the Oncology Centre in Bydgoszcz - analysis of more than six years of follow-up

Tomasz Nowikiewicz  1 , Magdalena Wiśniewska  2 , Michał Wiśniewski  3 , Marta Biedka  4 , Iwona Głowacka  5 , Dominika Kozak  5 , Ryszard Laskowski  1 , Wojciech Zegarski  5
Affiliations

Overall survival and disease-free survival in breast cancer patients treated at the Oncology Centre in Bydgoszcz - analysis of more than six years of follow-up

Tomasz Nowikiewicz et al. Contemp Oncol (Pozn). 2015.

Abstract

Aim of the study: Malignant breast tumours are the largest oncological problem in the developed world. In the recent years the number of new diagnoses has exceeded 16,500 per year. Published data regarding far-distant results of breast cancer treatment that take under consideration the provincial division of the country may not be representative of the therapeutic effects achieved in specific oncological centres. The goal of this article is to analyse far-distant therapeutic results in breast cancer patients treated at the Oncology Centre in Bydgoszcz in 2006. They were compared with data available for Kujawsko-Pomorskie Voivodeship and with all-Poland results.

Material and methods: A cohort of 667 breast cancer patients at Bydgoszcz Oncology Centre between Jan 1 and Dec 31, 2006 was studied. The majority of the studied group were patients in stage I (26.2%) and II (48.3%) according to the TNM staging system, 17.5% were in stage III, and 6.4% in stage IV. The 5-year survival and 5-year disease-free survival rates were calculated. Median observation time was 79 months.

Results: A total of 148 patients (22.2%) suffered a relapse. There were 168 (25.2%) deaths caused by primary disease. The 5-year survival probability was 0.761 ±0.017 and the five-year disease-free survival probability was 0.807 ±0.016. Median survival time was 76.4 months, and median disease-free survival was 19.4 months.

Conclusions: The five-year survival probability for breast cancer patients undergoing treatment at Bydgoszcz Oncology Centre was higher than all-Poland median five-year survival probability. The observation needs to be continued and should include the assessment of treatment in subsequent time periods.

Keywords: 5-year survival rate; breast cancer; mortality; treatment outcomes; treatment patterns.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Primary tumour size (cT) and TNM Classification of Malignant Tumours classification depending on place of patient's residence
Fig. 2
Fig. 2
Primary tumour size (cT) and TNM Classification of Malignant Tumours classification depending on place of patient's residence
Fig. 3
Fig. 3
Overall five-year survival (pOS) rate in the group of breast cancer patients treated at Bydgoszcz Oncology Centre in 2006
Fig. 4
Fig. 4
Disease-free survival probability (pDFS) rate in the group of breast cancer patients treated at Bydgoszcz Oncology Centre in 2006
Fig. 5
Fig. 5
Overall five-year survival (pOS) rate in the group of breast cancer patients depending on the disease stage
Fig. 6
Fig. 6
Disease-free survival probability (pDFS) rate in the group of breast cancer patients depending on the disease stage
See this image and copyright information in PMC

References

    1. Wojciechowska U, Didkowska J. Cancer in Poland in 2012. Nowotwory J Oncol. 2013;63:197–216.
    1. Didkowska J, Wojciechowska U. Breast cancer in Poland and Europe – population and statistics. Nowotwory J Oncol. 2013;63:111–8.
    1. Didkowska J, Wojciechowska U. Number of patients with diagnosed malignant diseases in Poland in 2006 – five-year prevalence. Nowotwory J Oncol. 2011;61:332–5.
    1. Kozierkiewicz A, Śliwczyński A, Jassem J, Topór-Mądry R, Paszkiewicz J. Breast cancer treatment patterns in Poland. Nowotwory J Oncol. 2012;62:250–62.
    1. Wojtyś P, Godlewski D, Andrzej Antczak A. Predictions of cancer incidence in Poland in 2019. Cent Eur J Med. 2013;8:185–91. - PMC - PubMed